Miyake Lab Home ¨ Publication List ¨ 2007-2009

 Pubication List: Original articles

2007-2009

1) Toba T, Murata K, Nakanishi K, Takahashi B, Takemoto N, Akabane M, Nakatsuka T, Imajo S, Yamamura T, Miyake S and Annoura H: Minimum structure requirement of immunomodulatory glycolipids for predominant Th2 cytokine induction and the discovery of non-linear phytosphingosine analogs. Bioorganic Med Chem Let 17:2781-2784, 2007

2) Kaieda S, Tomi C, Oki S, Yamamura T, Miyake S: Activation of iNKT cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis. Arthritis Rheum 56:1836-1845, 2007

3) Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, Yamamura T: Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 179:3452-3462, 2007

4) Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, Yamamura T, Kumar V, Berzofskky: Cross-regulation between Type I and Type II NKT cells in regulating turmor immunity: A new immunoregulatory axis. J Immunol 179:5126-5136, 2007

5) Oki S, Miyake S: Invariant Natural Killer T (iNKT) cells in asthma: A novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases. Allergol Int 56:7-14, 2007

6) Miyake S, Yamamura T: Therapeutic potential of CD1d-restriced invariant natural killer T cell-based treatment for autoimmune diseases. Int Rev Immunol 26:73-94, 2007

7) Miyake S, Yamamura T: NKT cells and autoimmune diseases: unrabeling the complexity. Cur Top Microbiol Immunol 314:251-267, 2007

8) Yamamura T, Sakuishi K, Illes Z, Miyake S: Understanding the behavior of invariant NKT cells in autoimmune diseases. J Neuroimmunol 1914:8-15, 2007

9) Miyake S, Yamamura T: NKT cells and Autoimmune Diseases: Unraveling the complexity. Current Topics in Microbiology and Immunology Moody DB, ed, Springer-Verlag, Heidelberg, 251-65 2007

10) Dondji B, Deak E, Goldsmith-Pestana K, Perez-Jimenez E, Esteban M, Miyake S, Yammaura T, McMahon-Pratt D: Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 38:706-19, 2008

11) Doi Y, Oki S, Ozawa T, Hohjoh H, Miyake S, Yamamura T: Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines. Proc Natl Acad Sci USA 105:8381-8386, 2008

12) Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, Miyasaka N, Kohsaka H: Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J Immunol 180:1954-1961, 2008

13) Yokote H, Miyake S, Croxford JL, Oki S, Mizusawa H, Yamamura T: NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Ame J Patho 173:1714-23, 2008

14) Okamoto T, Ogawa M, Lin Y, Murata M, Miyake S, Yamamura T: Treatment of neuromyelitis optica: Current debate. Therapeutic Advances Neurol 1 (1):43-52, 2008

15) Araki M, Miyake S, Yamamura T: Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy. Curr Med Chem 15(23):2337-2345, 2008

16) Theil MM, Miyake S, Mizuno M, Tomi C, Croxford J, Hosoda H, Theil J, von Horsten S, Yokote H, Chiba A, Lin Y, Oki S, Akamizu T, Kanagawa K, Yamamura T: Suppression of experimental autoimmune encephalomyelitis by Ghrelin. J Immunol. 83(4):2859-66, 2009

17) Fujita M, Otsuka T, Mizuno M, Tomi C, Yamamura T, Miyake S: Carcinoembryonic antigen-related cell adhesion molecule 1 modulates experimental autoimmune encephalomyelitis via iNKT cell-dependent mechanism. Ame J Patho 175(3):1116-23, 2009

18) Miyake S, Yamamura T. Ghrelin: friend or foe for neuroinflammation. Deicov Med 8(41):64-67, 2009


Miyake Lab, Dep of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry

4-1-1 Ogawa-higashimachi, Kodaira, Tokyo, 187-8502 Japan@@Tel: 042-341-2711@Fax: 042-346-1753
Copyright (C) 2010 Miyake Lab. All Rights Reserved.